Vineet Datta, Senior Director of Global Strategy at Datar Cancer Genetics Limited, shared a post on LinkedIn:
“Galleri, a blood test for detecting cancer early being developed by Grail failed to meet its main goal in a giant study being conducted with England’s National Health Service.
The focus on the biotech firm’s flagship NHS-Galleri trial, failed to meet its primary clinical endpoint of a statistically significant reduction in combined Stage III and IV cancer diagnoses.
The company reported a fourth-quarter net loss of $99.2 million, or ($2.44) per share, which significantly outperformed the consensus analyst estimate of a ($4.01) loss. Revenue for the period reached $43.6 million, representing 14% year-over-year growth, though the underlying clinical data overshadowed the financial beat.
‘The GRAIL news serves as a bellwether for the industry. We are moving away from the era of ‘one test, one result’ into an era of Agentic Diagnostic Workflows.’ ”
Title: The Signal in the Noise: Why GRAIL’s ‘Failed’ Endpoint is a Data Victory
Authors: Alex Burdenko
Read the Full Article.
Other articles featuring Vineet Datta on OncoDaily.